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Summary
Atopic dermatitis (AD) is associated with eczema vac-
cinatum (EV), a disseminated viral skin infection that
follows inoculation with vaccinia virus (VV). This
study examined whether AD skin can control VV repli-
cation, and the role of IL-4 and IL-13 in modulating the
human cathelicidin LL-37, an antimicrobial peptide
that kills VV. AD skin exhibited increased VV replica-
tion and decreased LL-37 expression compared to
normal or psoriasis skin. IL-4/IL-13 enhanced VV repli-
cation while downregulating LL-37 in VV-stimulated
keratinocytes. Neutralizing IL-4/IL-13 in AD skin aug-
mented LL-37 and inhibited VV replication. Cathelici-
dins were induced via toll-like receptor-3 and were
inhibited by IL-4/IL-13 through STAT-6. Skin from cath-
elicidin-deficientmice exhibited reducedability to con-
trol VV replication. Exogenous LL-37 controlled vac-
cinia viral replication in infected keratinocytes and
AD skin explants. The current study demonstrates
that Th2 cytokines enhance VV replication in AD skin
by subverting the innate immune response against
VV in a STAT-6-dependent manner.
Introduction
In 1980, the World Health Organization (WHO) declared
that endemic smallpox had been eradicated (World
Health Organization, 1980). The events of September
11, 2001, and the subsequent bioterrorist attacks with
anthrax have led to an unprecedented degree of con-
cern over potential future bioterrorist attacks with other
select agents such as smallpox and the plague (Lane
et al., 2001). It is estimated that 119 million residents of
the U.S. have been born since the smallpox vaccination
was discontinued. Such individuals are susceptible to
smallpox infection, an epidemic of which could result
in catastrophic numbers of death and disease (Bicknell,
*Correspondence: leungd@njc.org2002). This possibility has led to a debate over reinstat-
ing voluntary vaccinations against smallpox (Bicknell,
2002; Fauci, 2002; Drazen, 2002).
Individuals with atopic dermatitis (AD) are excluded
from voluntary smallpox vaccination due to their predis-
position to develop eczema vaccinatum (EV). The poten-
tial impact of this recommendation was seen recently
as up to 34% of military personnel deferred voluntary
smallpox vaccination, with various contraindications
with skin conditions being the main cause for deferral
(Grabenstein and Winkenwerder, 2003).
Approximately 17% of children are diagnosed with AD
(Leung et al., 2004; Leung and Bieber, 2003), and, ac-
cording to the current Centers for Disease Control guide-
lines, these children and those in close contact with
them should not be vaccinated (Rotz et al., 2001). It
is not understood why AD patients are susceptible to
developing EV. This prompted the National Institutes
of Health to fund the Atopic Dermatitis Vaccinia Network
to further investigate this important public health
concern (http://www.NIAID.NIH.gov/contract/archive/
RFP0406.pdf).
Antimicrobial peptides (AMPs) are an integral compo-
nent of the innate immune response that determines
susceptibility to infection (Ong et al., 2002; Dorschner
et al., 2001). Recently, our laboratory demonstrated
that the cathelicidin family, i.e., LL-37, of AMPs exhibit
antiviral activity against purified VV (Howell et al.,
2004). In an effort to understand the potential mecha-
nisms of EV, the current study was carried out to evalu-
ate the ability of cultured AD skin, as compared to nor-
mal or psoriasis skin, to control the replication of VV,
as well as the effect of IL-4 and IL-13, which are overex-
pressed in AD skin (Hamid et al., 1994), on the cathelici-
din response to VV infection.
Results
VV Replication in AD Skin Explant Cultures
Figure 1A demonstrates that VV replication was en-
hanced in biopsies from the uninvolved skin of AD pa-
tients (mean: 1241 6 485 ng VV/ng GAPDH) compared
to normal (mean: 312 6 44; p < 0.05) and psoriasis
(mean: 281 6 59; p < 0.05) skin. This finding was con-
firmed at the protein level by immunofluorescent stain-
ing for an early viral protein found in replicating VV
(Yuwen et al., 1993) (Figure 1B). Similar levels of VV
staining were observed in the stratum corneum of each
subject group; however, skin from AD patients exhibited
significantly more intense staining for VV in the basal
keratinocytes than did skin from normal (p < 0.05) and
psoriasis (p < 0.05) patients (Figure 1C).
AD skin is characterized by the overexpression of IL-4
and IL-13 (Hamid et al., 1994). We therefore examined
the direct effects of these Th2 cytokines on keratino-
cytes stimulated with VV (0.1 pfu/cell). Addition of IL-4
and IL-13 significantly augmented VV replication
(mean: 21,2806 4,814 ng VV/ng GAPDH; p < 0.001) com-
pared to media alone (mean: 12,760 6 1,263) (Figure 2).
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342Figure 1. Increased Vaccinia Virus Gene Expression in AD Skin
(A) RNA was isolated from nonlesional skin biopsies of normal (n = 7), AD (n = 7), and psoriasis (n = 6) patients stimulated with either media or
vaccinia virus for 24 hr and was analyzed for vaccinia virus gene expression by real-time RT-PCR. Data are expressed as the mean 6 SEM.
(B) Nonlesional skin biopsies from normal (n = 5), AD (n = 5), and psoriasis (n = 5) patients were stimulated with media or vaccinia virus for 24 hr
and were stained for E3L, an early vaccinia virus protein. Arrows point to intense vaccinia virus staining in basal keratinocytes of a representative
skin biopsy from each study group.
(C) The mean fluorescence intensity is shown for vaccinia virus expression in the basal keratinocytes of each biopsy.Essential Role of Cathelicidins in Controlling
VV Replication
To investigate the role of skin cathelicidins in the innate
immune response to VV, the gene expression of LL-37
was evaluated by real-time PCR in skin biopsies from AD
patients, psoriasis patients, and normal subjects that
were stimulated with VV. Stimulation with VV induced
significantly higher levels of LL-37 in normal (mean:
28.08 6 6.89 ng LL-37/ng GAPDH; p < 0.05) and psoria-
sis (mean: 30.56 6 6.65; p < 0.05) skin compared to the
media-stimulated biopsies from the same donors (nor-
mal mean: 10.60 6 2.39; psoriasis mean: 11.68 6 1.89)
(Figure 3A). In contrast, stimulation with VV failed to sig-
nificantly induce LL-37 expression in skin biopsies from
AD patients (media mean: 10.93 6 3.63; vaccinia mean:
11.226 3.90). This was confirmed at the protein level by
immunostaining for LL-37 (Figure 3B). VV-stimulated,
nonlesional skin from normal and psoriasis patients ex-
hibited more intense staining for LL-37 than did skin from
AD patients. The composite data for LL-37 immuno-
staining in all samples are shown in Figure 3C. The inten-
sity of LL-37 staining in vaccinia-stimulated, nonlesional
AD skin was significantly lower than that for normal (p <
0.05) and psoriasis (p < 0.01) skin. The basal cell layer ofAD skin, where VV replication was greatest (see Fig-
ure 1B), was relatively devoid of LL-37 staining, and it ex-
hibited much less staining than normalandpsoriasisskin.
Human keratinocyte cultures were infected with VV for
6 hr and then treated with exogenous LL-37 to determine
whether the virus replication could be halted with phys-
iologic concentrations of LL-37. Figure 4A demonstrates
that concentrations of LL-37 as low as 25 mM signifi-
cantly (p < 0.05) reduced the levels of VV gene expres-
sion in previously infected keratinocytes. This was fur-
ther investigated by stimulating skin biopsies from AD
patients with 2 3 105 pfu vaccinia for 6 hr, followed by
the addition of exogenous LL-37. Treatment with LL-37
significantly (p < 0.05) reduced viral replication in AD
skin biopsies (mean: 8.336 1.85 ng VV/ng GAPDH) com-
pared to VV alone (35.15 6 4.64 ng VV/ng GAPDH)
(Figure 4B). Additionally, we used mice deficient in
CRAMP, the murine homolog of LL-37, to further inves-
tigate the relationship between cathelicidins and VV
replication in the skin. Significantly higher levels of VV
replication were observed in skin biopsies from CRAMP
knockout mice (BALB/c background) (21.04 6 9.67 ng
VV/ng GAPDH; p < 0.05) compared to skin biopsies
from wild-type BALB/c mice (1.09 6 0.22) (Figure 4C).
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The mechanism by which VV induces LL-37 is not
known. Since VV is known to target the toll-like recep-
Figure 2. IL-4 and IL-13 Augment Vaccinia Virus Replication
Human keratinocytes were stimulated with vaccinia virus in the
presence and absence of IL-4 and IL-13 for 24 hr. RNA was collected
from the cells, and the levels of vaccinia virus were evaluated by real-
time RT-PCR. Data are expressed as the mean 6 SEM and are rep-
resentative of three experiments.tors (TLR) (Stack et al., 2005), we investigated whether
signaling through TLR-3 with polyinosinic-polycytidylic
acid (Poly I:C) would induce LL-37 in human keratino-
cytes. Stimulation with 250 mg/ml Poly I:C significantly
induced LL-37 expression (2.50 6 0.19 ng LL-37/ng
GAPDH; p < 0.01) compared to media alone (0.82 6
0.05). Levels were similar to those observed in keratino-
cytes stimulated with 0.1 pfu/cell VV (2.03 6 0.29) (Fig-
ure 5A). These data are representative of three indepen-
dent experiments. To further investigate the role of
TLR-3, skin biopsies from mice deficient in TLR-3 were
inoculated with VV. Levels of CRAMP were found to be
significantly decreased in TLR-3 knockout mice (0.62 6
0.08 ng CRAMP/ng GAPDH; p < 0.05) compared to wild-
type mice (2.84 6 0.78) (Figure 5B).
Th2 Cytokines Downregulate VV-Induced
LL-37 Expression through STAT-6
To further investigate why VV infection fails to signifi-
cantly induce LL-37 expression in AD, human keratino-
cytes were cultured in the presence of Th2 cytokines.
The addition of IL-4 and IL-13 prior to VV stimulation
(0.1 pfu/cell) reduced the levels of LL-37 by over 75%
(media alone mean: 1.29 6 0.13 ng LL-37/ng GAPDH;
IL-4/IL-13-treated mean: 0.166 0.01) (Figure 6). We nextFigure 3. Vaccinia Virus Fails to Induce LL-37 Expression in AD
(A) RNA was isolated from nonlesional skin biopsies of normal (n = 7), AD (n = 7), and psoriasis (n = 6) patients stimulated with either media or
vaccinia virus for 24 hr and was analyzed for LL-37 gene expression by real-time RT-PCR. Data are expressed as the mean 6 SEM.
(B) Nonlesional skin biopsies from normal (n = 5), AD (n = 5), and psoriasis (n = 5) patients were stimulated with media or vaccinia virus for 24 hr
and were stained for LL-37 immunohistochemistry.
(C) The intensity of the LL-37 immunostaining for each subject was visually scored on a scale from 0 to 3, with 0 indicating no staining and 3 in-
dicating the most intense staining.
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(A) Human keratinocytes were infected with 0.05 pfu/cell vaccinia virus for 6 hr and then treated with physiologic concentrations of LL-37 for an
additional 18 hr. RNA was isolated from the cells, and the levels of vaccinia virus gene expression were evaluated by real-time RT-PCR. Data are
expressed as the mean 6 SEM and are representative of three experiments.
(B) Skin biopsies from AD patients (n = 4) were stimulated with 2 3 105 pfu vaccinia virus for 6 hr and then treated with 100 mM LL-37 for an ad-
ditional 18 hr. RNA was isolated, and the levels of vaccinia virus gene expression were evaluated by real-time RT-PCR.
(C) Skin biopsies from BALB/c (n = 5) and CRAMP knockout (n = 5) mice were stimulated with 23 105 pfu vaccinia virus for 24 hr and evaluated for
vaccinia virus gene expression. RNA was collected from the tissue, and the levels of vaccinia virus were evaluated by real-time RT-PCR.investigated whether the defective anti-VV immune re-
sponse in AD skin could be reversed by the use of neu-
tralizing antibodies to IL-4 and IL-13. Nonlesional skin
biopsies were collected from AD patients and stimu-
lated with VV in the presence and absence of anti-IL-4/
anti-IL-13. Figure 7A demonstrates that neutralizationof IL-4 and IL-13 reduces the viral load by more than
75%—from 30,7406 8,091 ng VV/ng GAPDH to 7,3346
3,325 (p < 0.05). Additionally, LL-37 expression was
significantly increased in AD skin treated with anti-
IL-4/anti-IL-13 prior to VV stimulation (mean: 1531.5 6
329.3; p < 0.001) compared to AD skin stimulated withFigure 5. Vaccinia Virus Induces LL-37 by a TLR-3-Mediated Mechanism
(A) Human keratinocytes were stimulated with either vaccinia virus or Poly I:C for 24 hr. RNA was collected from the cells, and the levels of LL-37
were evaluated by real-time RT-PCR. Data are expressed as the mean 6 SEM and are representative of three experiments.
(B) Skin biopsies from wild-type (n = 6) and TLR-3 knockout mice (n = 6) were stimulated with 23 105 pfu vaccinia virus for 24 hr. RNA was isolated
from the skin and analyzed for CRAMP by real-time RT-PCR. Data are expressed as the mean 6 SEM.
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VV and LL-37 gene expression was not altered in normal
skin biopsies by the addition of anti-IL-4/anti-IL-13
(Figure S1; see the Supplemental Data available with
this article online). Since interferons (IFN) play an im-
portant role in the antiviral response, we investigated
whether treatment with anti-IL-4/anti-IL-13 would in-
crease IFN expression in AD skin. Treatment of AD skin
Figure 6. IL-4 and IL-13 Inhibit Vaccinia Virus-Induced LL-37
Human keratinocytes were stimulated with vaccinia virus in the
presence and absence of IL-4 and IL-13 for 24 hr. RNA was collected
from the cells, and the levels of LL-37 were evaluated by real-time
RT-PCR. Data are expressed as the mean6 SEM and are represen-
tative of three experiments.with anti-IL-4/anti-IL-13 prior to VV stimulation had no
effect on the levels of IFN-g (43.26 6 35.32 ng/ng
GAPDH), IFN-a1 (60.93 6 40.49 ng/ng GAPDH), or IFN-
b1 (31.15 6 20.29 ng/ng GAPDH) compared to VV stim-
ulation alone (IFN-g: 35.78 6 25.04; IFN-a1: 105.90 6
58.50; IFN-b1: 50.77 6 26.01) (Figure S2).
Skin biopsies from wild-type and signal transducer
and activator of transcription (STAT)-6-deficient mice
were stimulated with VV in the presence and absence
of IL-4 and IL-13. Wild-type skin treated with IL-4 and
IL-13 prior to VV stimulation exhibited significantly lower
levels of CRAMP (0.02 6 0.01 ng CRAMP/ng GAPDH;
p < 0.05), the murine homolog to LL-37, compared to
stimulation with VV alone (0.16 6 0.03). In contrast,
CRAMP levels were not affected by IL-4 and IL-13 in
the skin of STAT-6-deficient mice (VV alone: 0.34 6
0.16; VV + IL-4/IL-13: 0.09 6 0.06) (Figure 7C).
Discussion
Since there are currently no effective antiviral agents
that can be used to treat smallpox infection, inoculation
with VV remains the most effective method by which to
protect individuals from smallpox infection. Under-
standing the mechanism(s) that results in poor control
of VV in AD skin is critical to the development of new ap-
proaches for control of disseminated viral infections
such as EV and may provide insight into why specific
populations of humans are susceptible to adverse reac-
tions after smallpox vaccination. At this time, it is notFigure 7. IL-4 and IL-13 Inhibit Cathelicidin Expression through STAT-6 and Can Be Reversed by Neutralizing Antibodies
(A and B) Nonlesional skin from AD (n = 4) patients was preincubated with neutralizing antibodies to IL-4 and IL-13 versus control for 24 hr and
then stimulated with vaccinia virus for an additional 24 hr. These biopsies were then analyzed for (A) vaccinia virus and (B) LL-37 mRNA expres-
sion by real-time RT-PCR.
(C) Skin biopsies from wild-type (n = 5) and STAT-6 knockout mice (n = 5) were incubated with IL-4 and IL-13 for 24 hr and then stimulated with
vaccinia virus for an additional 24 hr. RNA was isolated from the skin and analyzed for CRAMP by real-time RT-PCR. NS indicates no significant
difference. Data are expressed as the mean 6 SEM.
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pox vaccine. Therefore, cultured human skin is a valu-
able approach for insights into mechanisms by which
VV infection causes EV.
To our knowledge, our current study is the first to
demonstrate that the skin of AD patients supports VV
growth to a greater extent than normal or psoriasis
skin. Increased levels of VV in AD skin were confirmed
by analyzing both gene expression of the DNA-depen-
dent RNA polymerase, which is essential for viral repli-
cation (Amegadzie et al., 1991), and immunofluorescent
staining for a double-stranded RNA binding protein
(Yuwen et al., 1993) expressed in the infectious cycle
of VV. We hypothesized that increased growth of VV in
AD skin results in the development of disseminated viral
infection clinically manifested as EV.
AMPs are an integral component of the innate immune
response and are one of the first lines of defense against
viral pathogens. We have previously shown that mem-
bers of the cathelicidin family of AMPs (i.e., LL-37), but
not human a defensin or human b defensins-1 or -2, pos-
sess antiviral activity against VV (Howell et al., 2004).
LL-37 is produced by keratinocytes (Frohm et al.,
1997) and is induced in response to inflammatory stimuli
(Erdag and Morgan, 2002). We therefore investigated the
levels of LL-37 in AD skin to determine whether in-
creased VV replication corresponded with decreased
AMP expression. After stimulation with VV, skin biopsies
from normal subjects and psoriasis patients expressed
increased levels of LL-37. In contrast, levels of LL-37 in
AD skin remained unchanged after VV stimulation. This
observation is important since LL-37 exhibits antiviral
activities, and it explains, in part, the increased growth
of VV observed in AD skin. The importance of cathelici-
dins in skin innate immune responses to VV is strongly
supported by our current observation that mice deficient
in CRAMP, the murine homolog to LL-37, exhibit higher
levels of VV replication after inoculation than do their
wild-type controls. Additionally, we demonstrate that
exogenous addition of LL-37 inhibits VV replication in
previously infected AD skin biopsies. This was further
extended to demonstrate that concentrations of LL-37
as low as 25 mM were able to inhibit VV replication in pre-
viously infected keratinocytes. Since psoriatic skin can
contain up to 1605 mM LL-37 (Ong et al., 2002), this dem-
onstrates that physiologic concentrations of LL-37 are
effective at controlling VV replication. This latter obser-
vation is particularly important since VV targets the
basal keratinocytes of AD patients, which corresponds
to the region of AD skin most deficient in LL-37.
It is not currently known how VV induces LL-37; there-
fore, we extended our studies to demonstrate that VV in-
duces LL-37 through TLR-3. This was demonstrated by
two approaches: first, by showing that the TLR-3 ago-
nist, Poly I:C, induces LL-37 to the same levels as VV
in cultured human keratinocytes. Second, we demon-
strate that VV does not induce CRAMP in TLR-3 knock-
out mice.
Uninvolved AD skin is characterized by overexpres-
sion of the Th2 cytokines IL-4 and IL-13, while it is rela-
tively devoid of the Th1 cytokines IL-12 and IFN-g (Ong
et al., 2002; Nomura et al., 2003). To our knowledge, our
current study is the first to demonstrate that IL-4 and
IL-13 augment VV replication in human keratinocytes,as evidenced by increased levels of VV gene expression.
It has previously been shown, by using knockout mice,
that a deficiency in IFN-g or IL-12 increases the suscep-
tibility to VV infection, whereas viral replication was im-
paired in IL-4 knockout mice (van den Broek et al.,
2000). The important role of IL-4 in pox infections was
further demonstrated by Jackson et al. (2001). Mice ge-
netically resistant to mousepox were infected with IL-4-
expressing Ectromelia virus (mousepox). These mice
developed symptoms of acute mousepox and signifi-
cant mortality due to mousepox.
Since keratinocytes are the primary source of AMPs in
the epidermis, we investigated the immunomodulatory
effect of IL-4 and IL-13 on the expression of LL-37 in hu-
man keratinocytes stimulated with VV. In this study, we
demonstrated that the addition of IL-4 and IL-13 to ker-
atinocytes inhibits the induction of LL-37. Thus, our cur-
rent study implicates the expression of IL-4 and IL-13 in
AD as the cause of deficient AMP production, and in-
creased VV replication that could contribute to the de-
velopment of EV in AD skin. To provide direct support
for this hypothesis, we demonstrated that inhibiting
the actions of IL-4 and IL-13, with neutralizing anti-
bodies, allows AD skin to act similarly to normal skin;
i.e., VV replication was reduced and LL-37 expression
was increased. Importantly, these data provide a ratio-
nale that neutralization of Th2 cytokine action in AD
skin may be considered to be a therapeutic approach
to boost innate immunity in AD skin and allow these in-
dividuals to be vaccinated against smallpox.
Th2 cytokines have previously been shown to act
through STAT-6 (Takeda et al., 1996a, 1996b), which
transcriptionally inhibits NF-kB binding to consensus
target sequences and the subsequent expression of in-
nate immune response genes (Ohmori and Hamilton,
2000). Since the expression of cathelicidins can be influ-
enced at several levels, including posttranslational
events such as enzymatic activation of the precursor
protein and release of the peptide from intracellular
granules, it was of interest to determine at what level
cathelicidin is regulated in VV-infected skin. The current
data show that both transcript abundance and cathelici-
din immunoreactivity are induced by VV. Furthermore,
by using STAT-6-deficient mice, we demonstrate that
IL-4 and IL-13 signal through STAT-6 to inhibit the ex-
pression of the cathelicidin transcript. As this process
correlates with antiviral activity and a NF-kB binding
site has been identified in the human cathelicidin pro-
moter (Pestonjamasp et al., 2001), it is likely that control
of cathelicidin expression in this system occurs, at least
in part, at the transcriptional level.
Since there is a significant life-long risk associated
with vaccination of AD patients, it is important to identify
potential therapeutic agents that would allow for the de-
velopment of an immune response while reducing the
potential for adverse events. Previous data from our lab-
oratory combined with this study would suggest the use
of LL-37 as an antiviral agent (Howell et al., 2004); how-
ever, recent studies have shown that this may not be op-
timal since LL-37 upregulates many components of the
inflammatory response (Braff et al., 2005) and may not
act systemically since it is a peptide and therefore sub-
ject to proteases. Based on our current study, we pro-
pose that further investigations into the neutralization
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reduce the risk for AD patients to develop EV and allow




Subjects included 16 patients with AD (mean age: 31.8 years; 20%–
60% skin involvement), 12 patients with psoriasis (mean age: 46.2
years; 15%–40% skin involvement), and 11 healthy individuals with
no history of skin disease (mean age: 31.2 years). None of the pa-
tients had previously received oral corticosteroids or cyclosporin,
and topical corticosteroids were not allowed for more than 1 week
prior to enrollment. This study was approved by the institutional
review board at National Jewish Medical and Research Center in
Denver, and all patients gave written informed consent prior to par-
ticipation in these studies.
Mice
BALB/c mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). Cnlp2/2 (CRAMP knockout) mice were obtained from
R.L. Gallo (Veterans Affairs Medical Center, San Diego, CA) and
were backcrossed onto the BALB/c background. TLR-3 knockout
and STAT-6 knockout mice were purchased from the Jackson Lab-
oratory. All animal protocols were approved by the Institutional
Animal Care and Use Committee at National Jewish Medical and
Research Center. This institution has an animal welfare assurance
number (A3026-1) on file with the Office of Protection and Research
Risks.
Virus Source and Culture
The Wyeth strain of VV was obtained from the Centers for Disease
Control and Prevention (Atlanta, GA). VV was propagated by using
HeLa S3 cells (ATCC#CCK-2.2) as previously described (Howell
et al., 2004). Virus was harvested, yielding infectious virions in the
form of intracellular mature virions (Schmelz et al., 1994).
Human Skin Explant Cultures
Punch biopsies (2 mm) were obtained from nonlesional skin of each
donor and were placed in a 96-well plate and RPMI (Cellgro) supple-
mented with 10% FCS (Gemini Bio Products). Biopsies were cul-
tured in the presence of media alone or 23 105 pfu VV for 24 hr. After
the exposure period, media were removed, and biopsies were sub-
merged in 10% buffered formalin for immunohistochemical staining,
or Tri-Reagent (Molecular Research Center, Inc., Cincinnati, OH) for
RNA isolation.
In some experiments, monoclonal anti-human IL-4 (1 mg/ml; R&D
Systems, Minneapolis, MN) and monoclonal anti-human IL-13 (1 mg/
ml; R&D Systems) were added to the skin biopsies for 24 hr prior to
infection with VV. After the infection, biopsies were cultured for an
additional 24 hr and prepared for RNA isolation.
To evaluate the antiviral activity of LL-37, skin biopsies were in-
fected with 2 3 105 pfu VV for 6 hr. After the incubation, VV was re-
moved, and the biopsies were washed with media to remove the re-
maining VV. LL-37 (100 mM) was added to the skin biopsies and
allowed to incubate for an additional 18 hr. RNA was isolated for
analysis of VV gene expression.
Murine Skin Explant Cultures
The dorsal thorax of all mice was clipped and treated with the depil-
atory agent Nair to remove hair. A total of 72 hr after hair removal,
mice were euthanized via carbon dioxide asphyxiation. Punch biop-
sies (6 mm) were collected from the dorsal thorax and immediately
placed in a 96-well plate and RPMI (Cellgro) supplemented with
10% FCS (Gemini Bio Products). Murine skin was cultured in the
presence of media alone or 2 3 105 pfu VV for 24 hr. After the expo-
sure period, media were removed, and biopsies were submerged in
Tri-Reagent (Molecular Research Center, Inc.) for RNA isolation.
STAT-6 knockout mice were first treated with murine IL-4 (50 ng/
ml; R&D Systems) and IL-13 (50 ng/ml; R&D Systems) for 24 hr prior
to infection with VV.Keratinocyte Cell Culture
Normal human epidermal keratinocytes were cultured in serum-free
Keratinocyte Growth Media (Clonetics, San Diego, CA) prepared
from the essential nutrient solution Keratinocyte Basal Medium sup-
plemented with 10 ng/ml epidermal growth factor, 0.4 mg/ml hydro-
cortisone, bovine pituitary extract, and antibiotics. HaCaT cells, a
human keratinocyte cell line, were cultured in Dulbecco’s modified
Eagle’s media (Cellgro) supplemented with 10% FCS (Gemini Bio
Products) and 1% of the following until confluent: penicillin/strepto-
mycin, L-glutamine, minimal essential medium with nonessential
amino acids (GIBCO-BRL), and MEM vitamins solution (GIBCO-
BRL).
To investigate the effects of the Th2 cytokines, cells were cultured
in the presence and absence of IL-4 (50 ng/ml; R&D Systems) and
IL-13 (50 ng/ml; R&D Systems) for 24 hr prior to stimulation with
VV. Cells were then infected with VV for an additional 24 hr. RNA
was isolated for analysis of VV gene expression and LL-37 by real-
time RT-PCR.
To evaluate the antiviral activity of LL-37, keratinocytes were in-
fected with 0.05 pfu/cell VV for 6 hr. After incubation, VV was re-
moved, and cells were washed with media to remove the remaining
VV. LL-37 (0–100 mM) was added to the cells and allowed to incubate
for an additional 18 hr. RNA was isolated for analysis of VV gene
expression.
To investigate the mechanism of LL-37 induction, Poly I:C (Amer-
sham Biosciences, Piscataway, NJ) was added to keratinocytes for
24 hr. RNA was isolated for analysis of LL-37 gene expression by
real-time RT-PCR.
Real-Time RT-PCR
Total RNA was isolated from skin biopsies by chloroform:phenol ex-
traction and isopropanol precipitation according to manufacturer’s
guidelines (Molecular Research Center, Inc.). RNeasy Mini Kits (Qia-
gen, Valencia, CA) were used according to the manufacturer’s pro-
tocol to isolate RNA from cell cultures and to further purify RNA
from skin biopsies. RNA was reverse transcribed into cDNA and an-
alyzed by real-time PCR by using an ABI Prism 7000 sequence de-
tector (Applied Biosystems, Foster City, CA) as previously described
(Nomura et al., 2003). Primers and probes for human GAPDH, IFN-g,
IFN-a1, and IFN-b1 were purchased from Applied Biosystems. VV
and LL-37 primer and probes were prepared as previously de-
scribed (Ong et al., 2002; Howell et al., 2004). Primer and probe
sequences used to assay CRAMP gene transcripts were: forward,
50-GCTGATTCTTTTGACATCAGCTGTA-30, reverse, 50-GCCAGCCG
GGAAATTTTCT-30. Quantities of all targets in test samples were nor-
malized to the corresponding GAPDH levels in cultured keratino-
cytes and skin biopsies.
VV Immunofluorescent Staining
Paraffin-embedded tissues were cut at 5 mm on frosted microscope
slides. Using toluene and a series of ethanol washes, slides were de-
paraffinized and then rehydrated. Skin sections were then blocked
with 5% BSA in Super Block (ScyTek Laboratories, Logan, UT) con-
taining 10% nonimmune donkey serum (Jackson Laboratories, West
Grove, PA) for 60 min. Slides were then stained with a mouse anti-
E3L antibody (gift from Dr. Bernard Moss, NIH/NIAID) directed
against an early viral protein located in the nucleus and cytoplasm
of infected cells (Amegadzie et al., 1991) or control mouse IgG1 at
4ºC overnight. Slides were washed with PBS/Tween 0.05%, fol-
lowed by incubation with a Cy3-conjugated donkey anti-mouse
IgG (Jackson Laboratories). Immunohistochemical staining was vi-
sualized with confocal microscopy (Leica, Wetzlar, Germany). Slides
were coded to ensure patient anonymity. Images were collected at
403, and levels of mean fluorescence intensity were measured
with Slidebook 3.0 (Intelligent Imaging Innovations, Denver, CO).
Mean fluorescence intensity (MFI) was determined for each expo-
sure group and was reported as mean MFI 6 SE.
LL-37 Protein Expression
Paraffin-embedded tissues were cut into 5 mm sections, deparaffi-
nized, rehydrated, and then stained with rabbit anti-LL-37 (5 mg/
ml) as previously described (Ong et al., 2002). Slides were coded
to ensure patient anonymity. Images were collected at 403magnifi-
cation, and the intensity of the immunostaining was scored on
Immunity
348a scale from 0 to 3, with 0 indicating no staining and 3 indicating the
most intense staining.
Statistical Analyses
All statistical analysis was conducted by using Graph Pad Prism,
version 3.01 (San Diego, CA). Statistical differences in gene expres-
sion or protein staining between multiple groups was determined by
using a one-way analysis of variance (ANOVA), and significant differ-
ences were determined by a Tukey-Kramer test (Tukey, 1977).
Supplemental Data
Supplemental Data including four figures and Experimental Proce-
dures are available at http://www.immunity.com/cgi/content/full/
24/3/341/DC1/.
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